Use of anakinra in treatment of combination of calcium pyrophosphate deposition desease and gout (clinical observation)

Abstract

Gout and calcium pyrophosphate crystal deposition disease (CPPD) are the most common inflammatory rheumatic diseases. It is known that the clinical manifestations of both diseases can simulate each other, in addition, cases of a combination of gout and CPPD are not uncommon, which complicates the diagnosis and selection of therapy. We present a case report of the successful use of the interleukin-1 beta (IL-1β) receptor antagonist Anakinra in a patient with a combination of gout and CPPD with chronic arthritis resistant to previous therapy with colchicine, non-steroidal anti-inflammatory drugs and glucocorticoids.